Michael Bishop, PhD

Michael Bishop, PhD

LinkedIn LogoMedicinal Chemistry Consultant, Bishop Drug Discovery Consulting, LLC

Mike Bishop started Bishop Drug Discovery Consulting LLC in San Diego in 2019 after 26 years as a medicinal chemist with the pharmaceutical company, GSK. As a consultant, Mike mainly supports small biotechs in their quest for new medicines across multiple therapeutic areas. With GSK, from 2001 to 2014, he directed a department of medicinal chemists and DMPK scientists with a focus on metabolic diseases, identifying ~10 clinical development candidates. From 2014 to 2019, Mike served as a Director in GSK’s Discovery Partnerships with Academia (DPAc) unit, with responsibilities for vetting of research opportunities, building collaborative workplans and leading joint drug discovery research programs with academic investigators. Mike’s passion is to work with expert teams and motivated entrepreneurs and use his expertise to drive therapeutic ideas to meaningful medicines.

Mike earned a B.A. in chemistry from Rice University in Houston, TX, worked in the petrochemical industry with Amoco Chemical in Texas City, TX for two years, and then returned to Rice, earning a Ph.D. in organic chemistry.

Related posts:

UNeMed President and CEO Michael Dixon, PhD, (right) presents UNMC researcher Rebekah Gundry,PhD, with the 2023 Emerging Inventor award during the Innovation Awards ceremony on Thursday, Nov. 2, 2023

Year in Review: Highlights from 2023

by Charles Litton, UNeMed | December 22, 2023 It’s that time again where we look back at the year that was 2023. In keeping with tradition, here’s a look at some of the more popular and important stories, events and happenings during the previous year: 1. Boot Camp When the Tech Transfer Boot Camp returned …

UNeMed Board expands, adds expertise from Boston and San Diego

OMAHA, Nebraska (November 17, 2023)—UNeMed announced today that Michael Bishop, PhD, and Kimberly Lamb, PhD, have joined its Board of Directors. “When the topic of new Directors came up,” UNeMed Chairperson Anne Barnes said, “we knew it was important for us add expertise from the strongest biotechnology clusters in the world and we couldn’t be …

Comments are closed.